Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Rating of “Buy” by Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has received a consensus rating of “Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $31.00.

A number of research analysts recently commented on the stock. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective on the stock. Leerink Partners assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 price target on the stock. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective for the company. Jefferies Financial Group initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. Finally, Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th.

Maplight Therapeutics Trading Up 4.8%

Shares of NASDAQ MPLT opened at $18.02 on Friday. The company has a market capitalization of $817.62 million and a PE ratio of -0.48. The company’s 50-day moving average is $16.70. Maplight Therapeutics has a fifty-two week low of $12.24 and a fifty-two week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.